Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy

Rationale: Lu-177-PSMA-617 radioligand therapy (RLT) is currently under approval for treatment of metastatic castration resistant prostate cancer (mCRPC) patients with late stage disease. However, previous studies demonstrated both heterogeneity of prostate specific membrane antigen (PSMA) expressio...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Theranostics
Glavni autori: Kessel, Katharina, Seifert, Robert, Weckesser, Matthias, Roll, Wolfgang, Humberg, Verena, Schlack, Katrin, Bögemann, Martin, Bernemann, Christof, Rahbar, Kambiz
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2020
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359074/
https://ncbi.nlm.nih.gov/pubmed/32685010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.44556
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items